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Abstract
When devising a course of treatment for a patient, doctors often have
little quantitative evidence on which to base their decisions, beyond their
medical education and published clinical trials. Stanford Health Care
alone has millions of electronic medical records (EMRs) that are only just
recently being leveraged to inform better treatment recommendations.
These data present a unique challenge because they are high-dimensional
and observational. Our goal is to make personalized treatment recom-
mendations based on the outcomes for past patients similar to a new
patient. We propose and analyze three methods for estimating heteroge-
neous treatment effects using observational data. Our methods perform
well in simulations using a wide variety of treatment effect functions, and
we present results of applying the two most promising methods to data
from The SPRINT Data Analysis Challenge, from a large randomized
trial of a treatment for high blood pressure.
1 Introduction
In February 2017, at the Grand Rounds of Stanford Medicine, one of us (N. S.)
unveiled a new initiative — the “Informatics Consult.” Through this service,
clinicians can submit a consultation request online and receive a report based on
insights drawn from hundreds of millions of electronic medical records (EMRs)
from Stanford Health Care. While the system is in its early stages, a future
version will include treatment recommendations: helping a doctor to choose
between treatment options for a patient, in cases where there is no randomized
controlled trial (RCT) which compares the options. This announcement was met
with excitement from the doctors in attendance, considering that they generally
need to make decisions without any support from quantitative evidence (about
95% of the time) (Shah, 2016). Building such a system is a priority in many
medical centers in the U.S. and around the world.
In the problem setting here a doctor is presented with a patient who has
some medical ailment, and the doctor is considering one or more treatment op-
tions. A relevant question from the patient’s perspective is, what is the effect
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of these treatments on patients like me? Devising a meaningful definition for
“patients like me” is especially difficult given the high-dimensional nature of
the problem: We may observe thousands of features describing each patients,
any of which could be used to describe patient similarity. The other significant
complication is that our goal is to infer causal effects from observational data.
The task of mining EMRs to support physician decision-making is what moti-
vates this paper. We propose and study methods for estimation and inference of
heterogeneous treatment effects, for both randomized experiments and observa-
tional studies. We focus on the case of a choice between two treatments, which
for the purposes of this manuscript we label as “treatment” and “control”.
In detail, we have an n×p matrix of features X, a treatment indicator vector
T ∈ {0, 1}n, and a vector of quantitative responses Y ∈ Rn. Let Xi denote the
ith row of X, likewise Ti and Yi. We assume the n observations (Xi, Ti, Yi) are
sampled i.i.d. from some unknown distribution. The number of treated patients
is N1 = |{i : Ti = 1}|, and the number of control patients is N0 = |{i : Ti =
0}|. We adopt the Neyman–Rubin potential outcomes model (Splawa-Neyman
et al., 1990; Rubin, 1974): each patient i has potential outcomes Y
(1)
i and Y
(0)
i ,
only one of which is observed. Y
(1)
i is the response that the patient would
have under treatment, and Y
(0)
i is the response the patient would have under
control. Hence the outcome that we actually observe is Yi = Y
(Ti)
i . We consider
both randomized controlled trials, where Ti is independent of all pre-treatment
characteristics, (
Xi, Y
(0)
i , Y
(1)
i
)
⊥ Ti, (1)
and observational studies, where the distribution of Ti is dependent on the
covariates. This latter scenario is discussed in further detail in Section 2.1.
We describe four important functions for modelling data of this type. The
first is the propensity function, which gives the probability of treatment assign-
ment, conditional on covariates:
pi(x) ≡ P(T = 1|X = x). (2)
The next two functions are the conditional mean functions: the expected re-
sponse given treatment and the expected response given control:
µ1(x) ≡ E[Y |X = x, T = 1] and µ0(x) ≡ E[Y |X = x, T = 0].
The fourth function, and the one of greatest interest, is the treatment effect
function, which is the difference between the two conditional means
τ(x) ≡ µ1(x)− µ0(x).
We seek regions in predictor space where the treatment effect is relatively
large or relatively small. This is particularly important for the area of personal-
ized medicine, where a treatment might have a negligible effect when averaged
over all patients but could be beneficial for certain patient subgroups.
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An outline of this paper is as follows. Section 2 reviews related work. In
Section 3 we describe the two high-level approaches to the estimation of het-
erogeneous treatment effects: transformed outcome regression and conditional
mean regression. Sections 4, 5, and 6 introduce pollinated transformed outcome
(PTO) forests, causal boosting, and causal MARS, respectively. In Section 7 we
report the results of a simulation study comparing all of these methods, and a
real data application is illustrated in Section 8. We end with a discussion.
2 Related work
Early work on heterogeneous treatment effect estimation (Gail and Simon, 1985)
was based on comparing pre-defined subpopulations of patients in randomized
experiments. To characterize interactions between a treatment and continuous
covariates, Bonetti and Gelber (2004) formalized the subpopulation treatment
effect patter plot (STEPP). Sauerbrei et al. (2007) proposed an efficient algo-
rithm for flexible model-building with multivariable fractional polynomial inter-
action (MFPI) and compared the empirical performance of MFPI with STEPP.
Identifying subgroups within the patient population is becoming especially
challenging in high-dimensional data, as in EMRs. In recent years, a great
amount of work has been done to apply methods from machine learning to en-
able the data to inform what are the important subgroups in terms of treatment
effect. Su et al. (2009) proposed interaction trees for adaptively defining sub-
groups based on treatment effect. Athey and Imbens (2016) proposed causal
trees, which are similar, and constructed valid confidence intervals.
The causal tree is the building block of our causal boosting algorithm in
Section 5, so we will briefly describe it here. A causal tree is like a decision tree
except that instead of estimating a mean outcome in each leaf we are interested
in estimating an average treatment effect. So the estimate in each leaf is not the
sample mean y¯ but rather y¯1−y¯0, the sample mean in the treatment group minus
the sample mean in the control group. Regression trees model a mean function
µ by finding the splits that maximize the heterogeneity of µ, so the causal tree,
which models τ , chooses the splits that result in the greatest heterogeneity in
τ . Athey and Imbens (2016) propose a few different criteria, and we will use
the T -statistic criterion: |τˆ` − τˆr|√
V̂ar(τˆ`) + V̂ar(τˆr)
.
When splitting a parent node into two child nodes ` and r, τˆ` and τˆr are the es-
timated treatment effects in each child node, with estimated variances V̂ar(τˆ`)
and V̂ar(τˆr), respectively. For the purposes of this manuscript we treat the
causal tree as estimating not just a treatment effect function fˆ(x) but two sep-
arate conditional mean functions gˆ(x, 1) and gˆ(x, 0) corresponding to treatment
and control groups, respectively, so that fˆ(x) = gˆ(x, 1)− gˆ(x, 0).
Wager and Athey (2015) improved on this line of work by growing random
forests (Breiman, 2001) from causal trees. These tree-based methods all use
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shared-basis conditional mean regression in the framework of Section 3. An
example of a transformed-outcome estimator is the FindIt method of Imai and
Ratkovic (2013) which trains an adapted support vector machine on a trans-
formed binary outcome. Tian et al. (2014) introduced a simple linear model
based on transformed covariates and show that it is equivalent to transformed
outcome regression in the Gaussian case. In a novel approach, Zhao et al. (2012)
used outcome weighted learning to directly determine individualized treatment
rules, skipping the step of estimating individualized treatment effects. The prob-
lem of estimating heterogeneous treatment effects has also received significant
attention in Bayesian literature. Hill (2011) and Green and Kern (2012) ap-
proached the problem using Bayesian additive regression trees (Chipman et al.,
1998), and Taddy et al. (2016) proposed a method based on Bayesian forests.
Chen et al. (2012) developed a Bayesian method for finding qualitative inter-
actions between treatment and covariates, and there are other Bayesian meth-
ods for flexible nonlinear modelling of interactive/non-additive relationships be-
tween covariates and response (LeBlanc, 1995; Gustafson, 2000).
What all of the above work (except Hill (2011)) have in common is that they
assume randomized treatment assignment. Athey and Imbens (2016) discussed
the possibility of adapting their method to observational data but go no fur-
ther. Wager and Athey (2015) proposed the propensity forest when treatment
is not randomized, but this method does not target heterogeneity in the treat-
ment effect. Similarly, Xie et al. (2012) model treatment effect as a function
of propensity score, missing out on how it depends on the covariates except
through treatment propensity. Crump et al. (2008) devised a nonparametric
test for the null hypothesis that the treatment effect is constant across patients,
but that is not suited to high-dimensional data. One promising approach which
flexibly handles high-dimensional and observational data is the generalization
of the causal forest by Athey et al. (2017). Their gradient forest addresses more
generally the problem of parameter estimation using random forests, and in par-
ticular they developed a very fast implementation of the causal forest against
which we compare the performance of our methods in Section 7.
2.1 Propensity score methods
Much of causal inference is based on the propensity score (Rosenbaum and
Rubin, 1983), which is the estimated probability that a patient would receive
treatment, conditioned on the patient’s covariates. If the estimate of the propen-
sity function (2) is pˆi(·), then the propensity score for a patient with covariate
vector x is pˆi(x). Throughout the present work, we estimate the propensity
function using the probability forests of Malley et al. (2012). We are able to do
so quickly using the fast implementation in the R package ranger (Wright and
Ziegler, 2015).
For the estimation of a population-average treatment effect (ATE), propen-
sity score methods for reducing bias in observational studies have been estab-
lished (Austin, 2011). Propensity score matching emulates a randomized control
trial (RCT) by choosing pairs of patients with similar propensity scores, one each
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in the treatment and control arms, and discards the unmatched patients. Strat-
ification on the propensity score groups patients into bins of similar propensity
scores to compute the ATE within each bin. The overall ATE is the average of
these treatment effects, weighted by the overall frequency of each bin. Inverse
probability weighting assigns a weight to each patient equal to the inverse of the
propensity score if the patient is treated, or else the inverse of one minus the
propensity score if the patient is not treated. Hence patients who tend to be
under-represented in their arm are given more weight. Propensity score strat-
ification and inverse probability weighting are discussed in more detail in the
appendix, along with an additional method: transformed outcome averaging.
The assumption that enables these methods to generate causal conclusions
from observational data is known alternatingly across the literature as uncon-
foundedness, exogeneity or strong ignorability:
(Y
(1)
i , Y
(0)
i ) ⊥ Ti|Xi
This is the assumption made in the present work. It means that the relationship
between each of the potential outcomes and treatment must be fully explained
by X. There can be no additional unmeasured confounding variable which
effects a dependence between potential outcomes and treatment. Note, however,
that the outcome itself is not independent of treatment because the treatment
determines which potential outcome is observed.
3 Transformed outcome regression and condi-
tional mean regression
Methods for estimating heterogeneous treatment effects generally fall into one
of two categories: transformed outcome regression and conditional mean regres-
sion. In this section we describe the two approaches and explain why we pre-
fer conditional mean regression. The propensity transformed outcome method
(Section 4) uses a combination of the two approaches, while causal forests (Sec-
tion 2), causal boosting (Section 5), and causal MARS (Section 6) are all con-
ditional mean regression methods.
Transformed outcome regression is based on the same idea as transformed
outcome averaging, which is laid out in detail in the appendix. Given the data
described in Section 1, we define the transformed outcome as
Z ≡ T Y
pi(X)
+ (1− T ) −Y
1− pi(X) .
This quantity is interesting because, as shown in the appendix, for any covariate
vector x, E[Z|X = x] = τ(x). So the transformed outcome gives us for each
patient an unbiased estimate of the personalized treatment effect for that pa-
tient. Using this, we can simply use the tools of supervised learning to estimate
a regression function for the mean of Z given X. The weakness of this approach
is that while Z is unbiased for the treatment effect, its variance can be large
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due the presence of the propensity score, which can be close to zero or one, in
the denominator.
An alternative approach— conditional mean regression — is based on the
idea that because τ(x) is defined as the difference between µ1(x) and µ0(x), if
we can get good estimates of these conditional mean functions, then we have
a good estimate of the treatment effect function. Estimating the functions
µ1(x) and µ0(x) are supervised learning problems. If they are both estimated
perfectly, then there is no need to estimate propensity scores. The problem
is that in practice we never estimate either function perfectly, and differences
between the covariate distributions in the two treatment groups can lead to bias
in treatment effect estimation if propensity scores are ignored.
We compare these two approaches with a simple example: Consider the task
of estimating an ATE using data from a randomized trial. This may seem far
removed from heterogeneous treatment effect estimation, but we will describe
how two of our methods are based on estimating local ATEs for subpopulations
in our data. In this case, the transformed outcome is
Z = T
Y
1/2
+ (1− T )−Y
1/2
= 2TY − 2(1− T )Y,
and the corresponding estimate of the ATE is
τˆTO =
1
n
n∑
i=1
Zi =
2N1Y¯1 − 2N0Y¯0
N1 +N0
=
N1
n/2
Y¯1 − N0
n/2
Y¯0,
where Y¯1 is the average response of patients who received treatment and Y¯0
is the average response of control patients. Meanwhile the conditional mean
estimator of the ATE would be
τˆCM = Y¯1 − Y¯0.
Here we are implicitly assuming that neither N1 nor N0 is zero. It is worth
noting that
τˆTO = τˆCM +
N1 −N0
n
(Y¯1 + Y¯0),
so if N1 = N0 or Y¯1 + Y¯0 = 0, then τˆTO = τˆCM. However N1, N0, Y¯1 and
Y¯0 are all random. Given a fixed sample size n, N1 follows a Binomial(n, 1/2)
distribution (truncated to exclude 0 and n), and N0 is the difference between n
and N1. Suppose Y¯1 and Y¯0 have normal distributions with variances inversely
proportional to sample size:
Y¯1 ∼ Normal(µ1, σ2/N1) and Y¯0 ∼ Normal(µ0, σ2/N0).
Note that both τˆCM and τˆTO are unbiased for τ ≡ µ1−µ0, but the two estimators
have different variances. Conditioning on N1, the variance of τˆCM is
E[(τˆCM − τ)2|N1] = V(Y¯1 − Y¯0|N1) = σ2/N1 + σ2/N0
6
Figure 1: The variance of two ATE estimators for n = 10, 30, 100 and 300, as
the ratio of the absolute main effect |µ1 + µ0|/2 to the noise level σ increases
from 0 to 0.5.
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while the variance of τˆTO given N1 is
E[(τˆTO−τ)2|N1] = V(τˆTO|N1)+(E[τˆTO−τ |N1])2 = 4
n
σ2+
(
N1 −N0
n
)2
(µ1+µ0)
2.
So the key is the ratio of the main effect (µ1 + µ0)/2 to the noise level σ. If∣∣∣∣µ1 + µ02σ
∣∣∣∣ <
√
N−11 +N
−1
0 − 4n−1
(N1 −N0)2 ,
then τˆTO has less variance. If the inequality is reversed, then τˆCM has less vari-
ance. Marginalizing over the truncated binomial distribution of N1 is difficult
to do analytically, but we can numerically estimate the marginal variance of
each estimator for any n > 1. Figure 1 illustrates the results for a few different
choices of n.
We observe that for small n, τˆTO can have slightly smaller variance than
τˆCM if the absolute value of the main effect is close to zero. But this advantage
tends to zero as n increases, and τˆTO has much greater variance if the main
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effect is large. In conclusion, we prefer the conditional mean estimator because
of the potentially high variance of the transformed outcome estimator. This
is reflected in the following sections as all of our methods use some version of
conditional mean regression.
3.1 Shared-basis conditional mean regression
In high-dimensional data it is often necessary to choose a subset of variables
to include in a model. Beyond that, nonparametric methods adaptively choose
transformations of variables. Collectively, we refer to the variables and transfor-
mations selected as the basis of the regression. In conditional mean regression it
is to be expected that the selected basis be different between the two regression
functions. This can cause differences between the conditional means attributable
not to a heterogeneous treatment effect but rather due to randomness in the
basis selection.
The three methods that we propose are based on two principles. First,
we prefer to use conditional mean regression rather than transformed outcome
regression, with a shared basis for the treatment and control arms. Second,
when adaptively constructing this basis, we want to do so in a way that reflects
the heterogeneity in the treatment effect, not the response itself. For example,
we want to include variables on which the treatment effect depends. How exactly
this shared basis is determined is different for each method.
4 Pollinated transformed outcome (PTO) forests
Our first method for estimating heterogeneous treatment effects is based on
the transformed outcome described in Section 3. The algorithm can be imple-
mented using pre-existing software packages for building random forests. We
first present the idea of a pollinated transformed outcome (PTO) forest in detail
and then explain its components.
We start with the transformed outcome, an unbiased point estimate of the
treatment effect for each individual; in step 1, we fit a random forest using
this effect as the outcome. In principal, this should estimate our personalized
treatment effect. Per Section 3, we don’t trust these estimates too much, because
the outcome can be highly variable. But we will put faith in the trees they
produced.
Thus in step 2, we “pollinate” the trees separately with the treated and
untreated populations. That is, we send data down each tree and compute new
predictions for each terminal node. The resulting estimates τˆi of the treatment
effect have lower variance, as explained in Section 3, because we are replacing a
transformed-outcome estimator with a conditional-mean estimator. Finally in
step 3, we can post-process these predictions by fitting one more forest, primarily
for interpretation.
Figure 2 illustrates the benefits of pollination. In this example n = 100, p =
50 and the response is simulated in each arm according to Yi ∼ N (1 − Xi1 +
8
Algorithm 1 Pollinated transformed outcome (PTO) forest
Require: Data (Xi, Ti, Yi), estimated propensity function pˆi(·)
Zi ← Ti Yipˆi(Xi) + (1− Ti) −Yi1−pˆi(Xi)
1. (Transformed outcome forest) Build a depth-controlled random forest
F on X to predict Z.
2. (Pollination) For each tree in the forest F , replace the node estimates
Z¯ with Y¯1 − Y¯0. This entails sending each observation down each tree
to get the mean response in treatment and control groups for each leaf,
replacing the mean transformed outcome. This yields treatment effect
estimates τˆi.
3. (Optional) Build an additional random forest G on X to predict τˆ .
This adds a layer of regularization and interpretability (through variable
importance) of the results.
Xi2, 1) for treated patients and Yi ∼ N (Xi1 + Xi2, 1) for untreated patients.
Hence the true personalized treatment effect for patient i is 1+2Xi1. In the top
row the treatment is randomly assigned, while in the bottom row, the probability
of treatment assignment is (1 + eXi1+Xi2)−1. The raw estimates correspond to
a random forest (as in step 2) grown to predict the transformed outcome. The
pollinated estimates correspond to re-estimating (as in step 3) the means of the
leaves within each arm. We observe that in each case, the pollination improves
the estimates.
5 Causal boosting
The PTO forest has the advantage of being implementable through pre-existing
software, but we would prefer to build our regression basis using conditional
means rather than the transformed outcome. The causal tree and causal forest
described in Section 2 accomplish this using specialized software. An alternative
to a random forest for least squares regression is boosted trees. Boosting builds
up a function approximation by successively fitting weak learners to the residuals
of the model at each step. In this section we adapt least squares boosting for
regression (Friedman, 2001) to the problem of heterogeneous treatment effect
estimation.
Given data of the form (Xi, Yi), i = 1, ..., n, least squares boosting starts with
a regression function Fˆ (x) = 0 and residuals Ri = Yi−Fˆ (xi). We fit a regression
tree to Ri, yielding predictions fˆ1(x). Then we update Fˆ (x)← Fˆ (x) +  · fˆ1(x),
and Ri ← Ri −  · fˆ1(xi) and repeat this (say) a few hundred times. The final
prediction is simply Fˆ (x), a sum of trees shrunk by .
For our current problem, our data has the form (Xi, Ti, Yi), i = 1, ..., n with
Ti ∈ {0, 1}. For now assume randomized treatment assignment: in the next
9
Figure 2: A comparison of raw and pollinated transformed outcome forests. Each
method is applied to a randomized simulation and a non-randomized simulation,
and we visually compare the estimated treatment effect with the true treatment
effect We see that in each case, the pollination improves the estimates. For
each method we report mean square error for the treatment effect estimates,
along with standard errors.
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subsection we show to handle the non-randomized case. Here is how we propose
to adapt least squares boosting. As with causal forests (Wager and Athey,
2015), our building block is a causal tree, which returns a function gˆ(x, t) as
described in Section 2. The estimated causal effect for an observation X = x
is τˆ(x) = gˆ(x, 1) − gˆ(x, 0). This is a standard causal tree, except that for each
terminal node, we return the pair of treatment-specific means rather than the
treatment effect. In other words, if observation Xi = x gets you into terminal
node k, where the pair of estimated means are µˆ1k (treated) and µˆ0k (untreated),
then these are the values returned, respectively, for gˆ(x, 1) and gˆ(x, 0). The
algorithm is summarized in Algorithm 2 below. The estimated treatment effect
for any observation x is GˆK(x, 1)− GˆK(x, 0).
Note that this generalizes to loss functions other than squared error. For
example, if the causal tree was trained for a binary outcome, then each terminal
node would return a pair of logits ηˆ1k = logit[Pr(Y = 1|X = x, T = 1)] and
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Algorithm 2 Causal boosting
Require: Data (Xi, Ti, Yi), parameters K,  > 0
Initialize Ri = Yi and Gˆ0(x, t) = 0.
for k in 1, ...,K do
Fit a causal tree gˆk to data (Xi, Ti, Ri)
Ri ← Ri −  · gˆk(Xi, Ti)
Gk ← Gˆk−1 +  · gˆk
end for
Return GˆK(x, t).
ηˆ0k = logit[Pr(Y = 1|X = x, T = 0)]. Thus GˆK(x, t) would be a function that
returned a pair of logits at x, and hence treatment success probabilities. The
treatment effect would be the appropriate function of these differences of log-
odds. Other enhancements to boosting, such as stochastic boosting, are also
applicable in the setting.
Note that causal boosting is not strictly a gradient boosting algorithm, be-
cause there is no loss function for which we are evaluating the gradient at each
step, in order to minimize this loss. Rather, causal boosting is an adaptation
of gradient boosting on the observed response, with a different function in each
arm of the data. The adaptation is that we use causal trees as our weak learners
instead of a standard regression technique. This tweak encourages the learned
function to find treatment effect heterogeneities.
5.1 Cross-validation for causal boosting
Unlike random forests, gradient boosting algorithms can over-fit the training
data as the number of trees increases (Hastie et al., 2009). This is because each
successive tree is not built independently of the previous ones but rather with
the goal of fitting to the residuals of the previous trees. Whereas a random
forest will only benefit from using more trees, the number of trees in gradient
boosting is itself an important parameter which needs to be tuned.
Complicating matters, the usual cross-validation framework does not apply
to the setting of estimating a heterogeneous treatment effect because in this
setting each observation does not come with a response corresponding directly
to the function we are interested in estimating. We don’t observe a response
τi for the i
th patient. What we observe is either Y
(0)
i or Y
(1)
i , depending on
whether or not the patient received the treatment.
We describe our approach in the context of a held-out validation set, but
this fully specifies our cross-validation procedure. Cross-validation is simply
validation done by partitioning the training set into several folds and averaging
the results obtained by holding out each fold as a validation set and training on
all other folds. The data in this context are a training set (Xtr,Ttr,Ytr) and a
validation set (Xv,Tv,Yv). After training causal boosting on (Xtr,Ttr,Ytr),
we are left with a sequence of models G1(x, t), ..., GK(x, t), and we would like to
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determine which of these models gives us the best estimates of treatment effect.
Our validation procedure uses a pollination of the causal boosting model
much like Step 2 of the PTO forest (Algorithm 1). We construct a new sequence
of models H1(x, t), ...,HK(x, t) using the same tree structures (split variables
and split points) as G1(x, t), ..., GK(x, t), but we send the validation points X
v
down each tree to get new estimates in the terminal nodes based on Tv and Yv.
The first causal tree gˆ1(x, t) is pollinated with the data (X
v,Tv,Yv), yielding
a new tree hˆ1(x, t). The validation-set residuals of this first tree are given by
Yi − hˆk(Xi, Ti), and these validation-set residuals are used to re-estimate the
terminal nodes of the next causal tree and so on. The sequential sum of these
trees (times the learning rate ) is H1(x, t), ...,HK(x, t).
We are ready to define our validation error for each of the original models
G1(x, t), ..., GK(x, t). The validation error for a causal boosting model with k
trees is given by∑
x∈v
({Gk(x, 1)−Gk(x, 0)} − {HK(x, 1)−HK(x, 0)})2 .
We have several remarks to make about this form. Gk(x, 1) − Gk(x, 0) is the
estimated treatment effect at x, for causal boosting with k trees. HK(x, 1) −
HK(x, 0) is the estimated treatment effect corresponding to the maximum num-
ber of trees, using the responses from the validation set. For a large number of
trees, we can be sure that this is over-fitting to the response, and this is the ana-
log of traditional cross-validation, which compares predictions on the validation
set with observed response in the validation set. This observed response, cor-
responding to the saturated model, is as over-fitted as possible. Intuitively, we
are comparing our estimated treatment effect for each validation point against
another estimate, which uses the same structure as the model fit to find similar
patients and estimate the treatment effect based on those similar patients, some
of whom will have received treatment, some of who will have received control.
The better the structure is that causal boosting has learned for the heteroge-
neous treatment effect, the more the local ATE in the training set will mirror
the local ATE in the validation set. For the results in Section 7, we use this
procedure to do cross-validation for causal boosting.
5.2 Within-leaf propensity adjustment
When the goal is to estimate not an ATE but rather an individualized treatment
effect, the propensity score methods described in Section 2.1 and in the appendix
do not immediately extend. Consider for example propensity score stratification.
Because each patient belongs to only one stratum of propensity score, we can
not average treatment effect estimates for a patient across strata. Technically,
if we were to fit a causal boosting model within each stratum, each of these
models would be able to make a prediction for the query patient. But then all
but one of these models would be unwisely extrapolating outside of its training
set to make this prediction. An alternative to propensity score stratification,
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inverse probability weighting is still viable, but the volatility of this method is
exacerbated by the attempt to estimate a varying treatment effect, rather than
a constant one.
Within each leaf of a causal tree, however, we estimate an ATE. This is where
causal boosting adjusts for non-random treatment assignment, using propensity
score stratification to reduce the bias in the estimate of the within-leaf ATE.
Before initiating the causal boosting algorithm, we begin by evaluating the
propensity score for each patient, which is an estimate of probability of being
assigned the treatment, conditioned on the observed covariates. Any binomial
regression technique could be used here. We fit a probability forest (Malley
et al., 2012), which is similar to a random forest for classification (Breiman,
2001) except that each tree returns a probability estimate rather than a classifi-
cation. The trees are combined by averaging the probability estimates and not
by majority vote. We denote the treatment assignment probability function by
pi(x) ≡ P(T = 1|X = x) and the corresponding propensity scores by pˆii ≡ pˆi(xi).
We group the patients into S strata of similar propensity scores denoted
1, ..., S. For example, there could be S = 10 strata, with the first comprising
pˆi ∈ [0, 0.1) and the last comprising pˆi ∈ [0.9, 1], with equal-length intervals
in between. We use si ∈ {1, ..., S} to denote the stratum to which patient i
belongs. Hence the data that we observe within each leaf of a causal tree are
of the form (Xi, si, Ti, Yi) ∈ Rp × {1, ..., S} × {0, 1} × R. We use n` to denote
the number of patients in leaf ` and index these patients by i = 1, ..., n`. The
propensity-adjusted ATE estimate in leaf ` is given by
τˆ` =
∑S
s=1 ns`(Y¯1s` − Y¯0s`)∑S
s=1 ns`
, where Y¯ts` =
∑n`
i=1 I{Ti=t∧si=s}Yi
nts`
(3)
is the mean response among the treatment (t = 1) or control (t = 0) group in
stratum s, and nts` =
∑n`
i=1 I{si=s} is the corresponding number of patients in
leaf ` for t ∈ {0, 1}, s ∈ {1, ..., S}. Finally, ns` = n1s` + n0s`.
The estimated variance of τˆ` is
V̂ar(τˆ`) =
∑S
s=1 n
2
s`σˆ
2
s`
(
∑S
s=1 ns`)
2
, where σˆ2s` =
s21s`
n1s`
+
s20s`
n0s`
,
and s2ts` is the sample variance of the response for arm t of stratum s in leaf `.
Hence, for two candidate daughter leaves ` and r of the same parent, The
natural extension of the squared T -statistic splitting criterion from Athey and
Imbens (2016) is
|τˆ` − τˆr|√
V̂ar(τˆ`) + V̂ar(τˆr)
.
This is the propensity-stratified splitting criterion used by causal boosting. This
criterion could also be used by a causal forest as it applies directly to its con-
stituent causal trees.
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We use this propensity adjustment not only for determining the split in a
causal tree but also for estimating the treatment effect in the node. Specifically,
the causal tree returns two values in each leaf: the propensity-adjusted mean
response in the treatment and control groups.∑S
s=1 ns`Y¯1sl∑S
s=1 ns`
and
∑S
s=1 ns`Y¯0sl∑S
s=1 ns`
.
6 Causal MARS
One drawback of tree-based methods is that there could be high bias in this
estimate because they use the average treatment effect within each leaf as the
prediction for that leaf. This is especially problematic when it comes to confi-
dence interval construction for personalized treatment effects. The variance of
the estimated treatment effect is relatively straightforward to estimate, but the
bias presents more of a challenge. We do not develop confidence intervals in this
manuscript, but we want to develop a more promising method for this endeavor
in future work.
Multivariate adaptive regression splines (MARS, Friedman (1991)) can be
thought of as a modification to CART which alleviates this bias problem. MARS
starts with the constant function f(x) = β0 and considers adding pairs of func-
tions of the form {(xj − c)+, (c − xj)+} and also the products of variables in
the model with these pairs, choosing the pair which lead to the greatest drop in
training error when they are added to their model, with regression coefficients
estimated via OLS. The difference between this and CART is that in CART the
pairs of functions considered are of the form {I{xj−c≥0}, I{c−xj>0}}, and when a
product with one of the included terms in chosen, it replaces the included term
in the model (Hastie et al., 2009). Because MARS does not replace but adds
terms, it can do a better job of capturing lower order regression functions.
We propose causal MARS as the adaptation of MARS to the task of treat-
ment effect estimation. We fit two MARS models in parallel in the two arms
(treatment and control) of the data, at each step choosing the same basis func-
tions to add to each model. The criterion that we use identifies the best basis
in terms of explaining treatment effect: we compare the drop in training error
from including the basis in both models with different coefficients to the drop in
training error from including the basis in both models with the same coefficient
in each model. The steps of causal MARS are as follows. The parameter D
controls the maximum dimension of the regression basis, and in practice we use
11 in our examples. Algorithm 3 has the details. In Section 7 we illustrate the
lower bias of causal MARS (relative to the causal forest) in a simulation.
To reduce the variance of causal MARS, we perform bagging by taking B
bootstrap samples of the original dataset and fitting the causal MARS model
to each one. The estimated treatment effect for an individual is the average of
the estimates for this individual by the B models. When bagging, we can save
on computation time by skipping the backward deletion and model selection
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Algorithm 3 Causal MARS
Require: Data (Xi, Ti, Yi), parameter D
Define F ≡ {{(xj − c)+, (c− xj)+} : c ∈ {Xij}, j ∈ {1, ..., p}}
Initialize B = {1}
βˆ ← argminβ
∑n
i=1
(
Yi − β1hITi=1 − β0hITi=0
)2
Ri ← Yi − βˆ1hITi=1 − βˆ0hITi=0
for d in 1, ..., D do
for {f, g} in {{b(x)f∗(x), b(x)g∗(x)} : b ∈ B, {f∗, g∗} ∈ F} do
RSSµ ← minβ
∑n
i=1
(
Ri −
∑
h∈{f,g} βhh(Xi)
)2
RSSτ ← minβ
∑n
i=1
(
Ri −
∑
h∈{f,g} β
1
hh(Xi)ITi=1 −
∑
h∈{f,g} β
0
hh(Xi)ITi=0
)2
dRSS = RSSτ −RSSµ
end for
Choose {f, g} which maximize dRSS
βˆ ← argminβ
∑n
i=1
(
Yi −
∑
h∈{f,g} β
1
hh(Xi)ITi=1 −
∑
h∈{f,g} β
0
hh(Xi)ITi=0
)2
Ri ← Yi −
∑
h∈{f,g} βˆ
1
hh(Xi)ITi=1 −
∑
h∈{f,g} βˆ
0
hh(Xi)ITi=0
B ← B ∪ {f, g}
end for
Backward deletion: delete terms one at a time, using the same criterion
dRSS = RSSτ −RSSµ
Use out-of-bag dRSS to estimate the optimal model size.
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steps in Algorithm 3. We found in simulation that this gives similar results to
including these steps.
Note that the algorithm described above applies to the randomized case, not
observational data. Given S propensity strata and membership s ∈ 1, ..., S, for
each patient, we use the same basis functions within each stratum but different
regression coefficients. Within each stratum, the coefficients are estimated sepa-
rately from the coefficients in other strata. Given the entry criterion dRSSs and
number of patients ns in each stratum, we combine these into a single criterion∑
s nsdRSSs. This is the propensity-adjusted causal MARS.
7 Simulation study
In the design of our simulations to evaluate performance of methods for hetero-
geneous treatment effect estimation, there are four elements to the generation
of synthetic data:
1. The number n of patients in the training set, and the number p of features
observed for each patient.
2. The distribution DX of the feature vectors Xi. Across all scenarios,
we draw odd-numbered features independently from a standard Gaus-
sian distribution. We draw even-numbered features independently from a
Bernoulli distribution with probability 1/2.
3. The propensity function pi(·), the mean effect function µ(·) and the treat-
ment effect function τ(·). We take the conditional mean effect functions
to be µ1(x) = µ(x) + τ(x)/2 and µ0(x) = µ(x)− τ(x)/2.
4. The conditional variance σ2Y of Yi given Xi and Ti. This corresponds to
the noise level, and for most of the scenarios σ2Y = 1. In Scenarios 2 and
4 the variance is lower to make the problem easier; in Scenarios 7 and 8
the variance is higher.
Given the elements above, our data generation model is, for i = 1, ..., n:
Xi
i.i.d.∼ DX
Ti
ind.∼ Bernoulli(pi(Xi))
Yi
ind.∼ Normal (µ(Xi) + (Ti − 1/2)τ(Xi), σ2Y )
The third element above, encompassing pi(·), µ(·) and τ(·), is most interest-
ing. Note that pi(·) and µ(·) are nuisance functions, and τ(·) is the function we
are interested in estimating. In this section, we present two batches of simula-
tions, the first of which represent randomized experiments. The second batch of
simulations represent observational studies. Within each set of simulations, we
make eight different choices of mean effect function and treatment effect func-
tion, meant to represent a wide variety of functional forms: both univariate and
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multivariate; both additive and interactive; both linear and piecewise constant.
The eight functions that we chose are:
f1(x) = 0 f2(x) = 5I{x1>1} − 5 f3(x) = 2x1 − 4
f4(x) = x2x4x6 + 2x2x4(1− x6) + 3x2(1− x4)x6 + 4x2(1− x4)(1− x6) + 5(1− x2)x4x6
+6(1− x2)x4(1− x6) + 7(1− x2)(1− x4)x6 + 8(1− x2)(1− x4)(1− x6)
f5(x) = x1 + x3 + x5 + x7 + x8 + x9 − 2
f6(x) = 4I{x1>1}I{x3>0} + 4I{x5>1}I{x7>0} + 2x8x9
f7(x) =
1
2
(
x21 + x2 + x
2
3 + x4 + x
2
5 + x6 + x
2
7 + x8 + x
2
9 − 11
)
f8(x) =
1√
2
(f4(x) + f5(x))
Each of the eight functions above is centered and scaled so that with respect
to the distribution DX , each has mean close to zero and all have roughly the
same variance. Table 1 gives the mean and treatment effect functions for the
eight randomized simulations, in terms of the eight functions above. In these
simulations pi(x) = 1/2 for all x ∈ Rp. In addition to the methods described
in Sections 4, 5 and 6, we include results for four additional estimators for
comparison. First, the null estimator is simply the difference Y¯1 − Y¯0 in mean
response between treated and untreated patients. This provides a naive baseline.
Second, the transformed outcome (TO) forest is a random forest built on the
transformed outcome, as in Step 1 of Algorithm 1. Hence it is a straightforward
transformed outcome regression as in Section 3. Third, the different basis (DB)
forest are two separate forests constructed, one predicting the response in the
control group and the other predicting the response in the treatment group.
The difference between these two predictions is the estimated treatment effect.
This method reflects conditional mean regression from Section 3 without using
a shared basis. The other competitor is the causal forest of Athey et al. (2017),
using the gradient.forest R package made available online by the authors.
The results of the first batch of simulations are shown in Figure 3.
If we pick “winners” in each of the simulation scenarios based on which
method has the lowest distribution of errors, causal MARS would win Scenarios
5, 7 and 8, tying with the pollinated transformed outcome forest in Scenario 4.
The PTO forest would win Scenarios 2 and 3, tying with causal boosting in
Scenario 6. In general all of the methods outperform the null estimator except
in Scenario 1, when the treatment effect is constant, and in Scenario 6, when the
causal forest performed worst. We also observe that the transformed outcome
regression (TO) and conditional mean regression without shared basis (DB)
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Table 1: Specifications for the 16 simulation scenarios. The four rows of the
table correspond, respectively, to the sample size, dimensionality, mean effect
function, treatment effect function and noise level. Simulations 1 through 8 use
randomized treatment assignment, meaning pi(x) = 1/2. Simulations 9 through
16 have a bias in treatment assignment, specified by (4).
Scenarios 1, 9 2, 10 3, 11 4, 12 5, 13 6, 14 7, 15 8, 16
n 200 200 300 300 400 400 1000 1000
p 400 400 300 300 200 200 100 100
µ(x) f8(x) f5(x) f4(x) f7(x) f3(x) f1(x) f2(x) f6(x)
τ(x) f1(x) f2(x) f3(x) f4(x) f5(x) f6(x) f7(x) f8(x)
σ2Y 1 1/4 1 1/4 1 1 4 4
estimators are not competitive with the ones that we propose, illustrating the
value of shared-basis conditional mean regression.
The second batch of simulations matches the parameters listed in Table 1:
Scenario 9 is like Scenario 1; Scenario 10 is like Scenario 2; and so on. The
difference is in the propensity function. For this second batch of simulations,
we use
pi(x) =
eµ(x)−τ(x)/2
1 + eµ(x)−τ(x)/2
. (4)
The interpretation of this propensity function is that patients with greater mean
effect are more likely to receive the treatment. This resembles a situation in
which greater values of the outcome are worse for the patient, and only patients
who have need for treatment will receive it. There are many possible forms
for the propensity function, but we focus on this one because it is particularly
troublesome, and a good estimator of the treatment effect needs to avoid the
pitfall of over-estimating the effect because the treated patients have greater
mean effect. This is exactly the kind of bias we are most concerned about in
observational studies. The results of this second batch of simulations are shown
in Figure 4.
In the batch of simulations with biased treatment assignments, propensity-
adjusted causal boosting shines. In six of the eight simulations, causal boosting
as either the lowest error distribution or is one of the two methods with the
lowest error distribution. Curiously, in Scenario 13, unadjusted causal MARS
performs very well, but the propensity adjustment ruins this performance. In
Scenario 15, PTO forest and causal forest produce the best results though all of
the methods perform well. Overall, across the 16 simulation scenarios, causal
boosting and causal MARS stand out as having the best performance.
Figure 5 illustrates the promised reduction in bias achieved by causal MARS
relative to the causal forest, in Scenario 8. In this scenario we have the most
complex treatment effect function, with quadratic terms and stepwise inter-
actions between variables. With a large number of observations (n = 1000)
relative to the number of variables (p = 100), it pays to use the more flexible
causal MARS algorithm, which has much lower bias than the causal forest. The
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Figure 3: Results across eight simulated randomized experiments. For details of
the generating distributions, see Table 1. The seven estimators being evaluated
are: NULL = the null prediction, TO = transformed outcome forest, DB = dif-
ferent basis forest, CF = causal forest PTO0 = pollinated transformed outcome
forest (using propensity = 1/2), CB0 = causal boosting, BCM0 = bagged causal
MARS. The ranges of the y-axis are chosen to start from zero and be at least as
great as the response standard deviation in each scenario while showing at least
95% of the data.
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Figure 4: Results across eight simulated observational studies, in which treat-
ment is more likely to be assigned to those with a greater mean effect. The
seven estimators being evaluated are: NULL = the null prediction, CF = causal
forest, PTO = pollinated transformed outcome forest, CB1 = causal boosting
(propensity adjusted), CB0 = causal boosting, CM1 = causal MARS (propensity
adjusted), BCM0 = bagged causal MARS. CB0 and BCM0 are in gray because
they would not be used in this setting. They are provided for reference to assess
the effect of the propensity adjustment. The ranges of the y-axis are chosen to
start from zero and be at least as great as the response standard deviation in
each scenario while showing at least 95% of the data.
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Figure 5: Illustration of the bias of causal forest and causal MARS. Patient
features were simulated once, and then treatment assignment and response were
simulated 50 times. Causal forest and causal MARS were applied to each of the
50 simulations, and the average estimate for each patient is plotted below.
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greater flexibility comes at the cost of greater variance, but reducing the bias
makes for a more promising candidate for confidence interval construction in
future work.
8 Application
In September 2016, New England Journal of Medicine opened The SPRINT
Data Analysis Challenge, based on the complete dataset from a randomized
trial of a novel intervention for the treatment of high blood pressure (SPRINT
Research Group, 2015). The goal was open-ended: to draw novel or clinically
useful insights from the SPRINT dataset, possibly in tandem with other publicly
available data.
The intervention in the randomized trial (SPRINT Research Group, 2015)
was a more intensive control of systolic blood pressure (target 120 mm Hg)
than is standard (target 140 mm Hg). The primary outcome of interest was
whether the patient experienced any of the following events: myocardial in-
farction (heart attack), other acute coronary syndrome, stroke, heart failure or
death from cardiovascular causes. The trial, which enrolled 9361 patients, ended
after a median follow-up period of 3.26 years, when researchers determined at
a pre-planned checkpoint that the population-average outcome for the intensive
treatment group (1.65% incidence per year) was significantly better than that
of the standard treatment group (2.19% incidence per year).
In addition to the primary event, for each patient researchers tracked several
other adverse events, as well as 20 baseline covariates recorded at the moment of
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Figure 6: Personalized treatment effect estimates from causal boosting and
(bagged) causal MARS. Each circle represents a patient, who gets a personal-
ized estimate from each method. The dashed line represents the diagonal, along
which the two estimates are the same.
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treatment assignment randomization: 3 demographic variables, 6 medical his-
tory variables and 11 lab measurements. The question that we seek to answer
in this section is whether we can use these variables to give personalized esti-
mates of treatment effect which are more informative than the population-level
average treatment effect. To answer this question, we apply causal boosting and
bagged causal MARS to these data.
Of the 9361 patients who underwent randomization, 1172 (12.5%) died, dis-
continued intervention, withdrew consent or were lost to follow-up before the
conclusion of the trial. There is little evidence (χ2 p-value = 31%) that this
censorship was more common in either arm of the trial. To extract a binary
outcome from these survival data, we use as our response the indicator that a
patient experiences the primary outcome within 1000 days of beginning treat-
ment, ignoring patients who were censored before 1000 days. Additionally, we
dropped the 1.8% of patients who have at least one lab measure missing. This
leaves us with a sample of 7344 patients, which we split into equally sized train-
ing and validation sets.
The results of fitting causal boosting and bagged causal MARS on the train-
ing sample of 3672 patients are shown in Figure 6. We proceeded with these two
methods based on their strength in the simulation study. We observe that the
two methods yield very different distributions of estimated personalized treat-
ment effects in the aggregate. Causal boosting produces estimates resembling
a normal distribution with a standard deviation of about 3.5% risk. In con-
trast, bagged causal MARS estimates almost all patients to have a treatment
effect between −5% risk and +0% risk, but for a small percentage of patients
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Figure 7: Decision trees summarizing with broad strokes the inferences of causal
boosting and (bagged) causal MARS. The variables are: trr triglcerides (mg/dL)
from blood draw; age age (years) at beginning of trial; glur glucose (mg/dL)
from blood draw; screat creatinine (mg/dL) from blood draw; umalcr albu-
min/creatinine ratio from urine sample; dbp diastolic blood pressure (mm Hg);
egfr estimated glomerular filtration rate (mL/min/1.73m
2
). If the inequality at
a split is true for a patient, then that patient belongs to the left daughter node.
Causal boosting
|trr>=206.5
age>=60.5 glur< 97.5
glur>=94.5 screat< 0.955
−6.6 0.55
−4.5 −1.6
−2.3 1.1
Causal MARS
|umalcr< 1874
dbp>=63.5
umalcr< 356.6
umalcr< 71.93
egfr>=52.92 dbp>=56.5
−2
−1.7 1.1
1.6 13
18
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the treatment effect is much greater or much lesser. The tails of this distribu-
tion are much heavier than that of a normal distribution. In fact, a very small
number of patients (0.4% of the training sample) are not included in this figure
because their treatment effect estimate from bagged causal MARS falls outside
of the plotted region.
Figure 7 depicts decision trees which summarize the key inferences made by
causal boosting and bagged causal MARS. Each leaf gives the average estimated
treatment effect for patients who belong to that leaf. Such a decision could be
reported to a physician to explain the basis for these personalized treatment
effect estimates. According to causal boosting, for example, older patients with
high triglycerides stand to gain more from the intensive blood pressure treat-
ment than younger patients with high triglycerides. Among patients with low
triglycerides and high glucose, those with low creatinine stand to benefit more
from the intensive treatment than those with high creatinine. The decision tree
for bagged causal MARS makes the extreme claim that for patients with urine
albumin/creatinine ratio above 1874, the average treatment effect is a 21% in-
crease in risk. Discussions with practitioners suggest that the distribution of
personalized treatment effects estimated by causal boosting is more plausible
than that of bagged causal MARS. As such, we focus our interpretation on the
results of causal boosting for the reminder of this section.
To simplify the results even more than the decision tree does, we note that for
both causal boosting and bagged causal MARS, the two features which correlate
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Figure 8: Training set personalized treatment effects, estimated via causal
boosting and (bagged) causal MARS, versus estimated glomerular filtration rate
(eGFR). Patients are stratified according to eGFR on the x-axis, and each point
gives the average personalized treatment effect among patients in that stratum.
Error bars correspond to one standard error for the mean personalized treatment
effect. The vertical dashed line represents a medical cutoff, below which patients
are considered to suffer from chronic kidney disease.
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Causal MARS
most to the personalized treatment effect estimates are estimated glomerular fil-
tration rate (eGFR) and creatinine. These two variables are highly correlated
with each other, as creatinine is one of the variables used to estimate GFR.
Both are used to assess kidney health, and patients with eGFR below 60 are
considered to have chronic kidney disease (CKD). Figure 8 shows the relation-
ship between eGFR and the estimated personalized treatment effects from both
methods. Despite there being no manual notation in the data that there is
something special about an eGFR of 60, we have learned from causal boost-
ing that patients below this cutoff have less to gain from the intensive blood
pressure treatment than patients above this cutoff.
Note that we are not only interested in whether a patient’s personalized
treatment effect is positive or negative. Intensive control of blood pressure
comes with side effects and should only be assigned to patients for whom the
benefit of reducing the risk of an adverse coronary event is substantial. The
results of causal boosting on the training set suggest that patients with CKD
have less to gain from this treatment than do other patients.
8.1 Validation
The results above tell an interesting story: If you are a patient with CKD (eGFR
< 60), you are expected to benefit less from intensive blood pressure control.
As discussed in Section 5.1, validating treatment effect estimates is challenging
because we do not observe the treatment effect for any individual patient. In
this section, we make an attempt to validate the more general conclusion from
24
Figure 9: Validation set personalized treatment effects, estimated via causal
boosting and (bagged) causal MARS, versus estimated glomerular filtration rate
(eGFR). Patients are stratified according to eGFR on the x-axis, and each point
gives the average personalized treatment effect among patients in that stratum.
Error bars correspond to one standard error for the mean personalized treatment
effect. The vertical dashed line represents a medical cutoff, below which patients
are considered to suffer from chronic kidney disease.
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the previous section: that the treatment has less benefit for patients with CKD.
Figure 9 shows the results of fitting causal boosting and bagged causal MARS
on the held-out validation set of 3672 patients. Bagged causal MARS again picks
up on a similar negative relationship between eGFR and the treatment effect.
Meanwhile causal boosting does not tell the same story as in the training set.
For these estimates, there is no clear relationship with eGFR in the validation
set.
It is promising that at least bagged causal MARS leads us to the same finding
as both methods do in the training set. The team from Boston University
which placed second in the SPRINT Data Analysis Challenge made the same
finding as shown in the causal boosting results. They found that intensive
blood pressure management does not improve primary outcomes for patients
with CKD (Aggarwal et al., 2017). Something that the authors do not address
is why they chose to analyze patients with CKD. Presumably they used some
combination of prior medical knowledge and manual hypothesis selection. In
our training set, we came to the same conclusion using both methods without
the benefit of either of these steps. The lack of agreement by causal boosting
on the validation set could be explained by insufficient power.
9 Discussion
We have proposed and compared a number of different methods for estimating
heterogeneous treatment effects from high-dimensional covariates. The causal
boosting and bagged causal MARS approaches seem particularly promising in
25
simulations. Both of these methods found in the SPRINT data a relationship
between kidney health and the treatment effect that has also been identified by
other researchers (Aggarwal et al., 2017). An important next step is confidence
interval construction. We have developed causal MARS so that it would be
conducive to confidence interval construction, but we leave this task to future
work.
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